Skip to main content

AbbVie Inc. company profile

  • ABBV · NYSE
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$295.03+0.20%Close 13 Nov 2026 · Market value $524.5B

About AbbVie Inc.

AbbVie Inc. is a global, research-based biopharmaceutical company that operates as a single business segment engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. Its portfolio spans immunology, neuroscience, oncology and aesthetics, with products including Skyrizi, Rinvoq, Humira, Vraylar, Botox Therapeutic, Imbruvica, Venclexta, Botox Cosmetic and Juvederm Collection. The company sells primarily to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers, and also to managed care providers, hospitals and physicians. Its products are sold worldwide, with a significant U.S. presence and sales in markets across North America, the European Union, Japan and other regions.

A summary of the business section of the company's latest annual report, filed 20 Feb 2026.

Company facts

TickerABBV · NYSE
SectorPharmaceuticals
IndustryBiotechnology
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK1551152
Latest annual report10-K, filed 20 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
A. Saleki-GerhardtEVP, CHIEF OPERATIONS OFFICER204KShares withheld for tax, 27 Feb 2026
R. MichaelCHAIRMAN OF THE BOARD AND CEO · Director179KShares withheld for tax, 27 Feb 2026
T. FreymanDirector135KGrant or award, 8 May 2026
R. ThakkarEVP, R&D and CSO55.4KShares withheld for tax, 27 Feb 2026
S. ReentsEVP, CHIEF FINANCIAL OFFICER38.8KShares withheld for tax, 27 Feb 2026
R. AustinDirector38.5KGrant or award, 8 May 2026
R. AlpernDirector35.6KGrant or award, 9 May 2025
F. WaddellDirector29.0KGrant or award, 8 May 2026
W. BurnsideDirector27.0KGrant or award, 8 May 2026
M. MeyerDirector16.5KGrant or award, 8 May 2026
R. RobertsDirector13.7KGrant or award, 8 May 2026
J. DavisDirector2.5KGrant or award, 8 May 2026
S. QuagginDirector2.5KGrant or award, 8 May 2026
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER—Gift, 12 Nov 2026
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER—Option exercise, 14 Aug 2026
Hart Brett JDirector—Grant or award, 8 May 2026
FALK THOMAS JDirector—Grant or award, 8 May 2026
RAPP EDWARD JDirector—Grant or award, 8 May 2026
Purdue David RyanSVP, Controller—Open-market sale, 4 Mar 2026
Siatis Perry CEVP, GC AND SECRETARY—Sale under a 10b5-1 plan, 2 Mar 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

ABBV in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.